Appointments
Adam Rosenberg replaces Dr Carlo Incerti as new chair of the board at VectorY Therapeutics
VectorY Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacing Dr Carlo Incerti.
With over 20 years of experience founding and leading life sciences businesses, there is little question that VectorY Therapeutics has a bright future ahead thanks to Rosenburg’s notable leadership skill and proficiency in disorders of the central nervous system.
Sander van Deventer, founder and CEO of VectorY comments on the new appointment: “As we welcome Adam to VectorY as chair of the board, I would also like to thank Carlo for his leadership, guidance and dedication to VectorY since our founding. Adam is a seasoned biotech and independent executive with a proven track record in building successful businesses and teams. I am excited to be working with Adam and our board as VectorY advances to its next phase of growth, from a preclinical to clinical stage company and as we expand our footprint in the US.”
In addition to serving as a chief executive officer, director and chair on the boards of world-renowned biotechnology firms such as Seamless Therapeutics and Ambagon Therapeutics, Adam held the positions of CEO and co-founder of Link Medicine, a successful business dedicatedtocreatingdisease-modifying neurodegenerative therapies.
Speaking of his new role, Adam Rosenberg reports: “I am delighted to join VectorY at such a pivotal moment in the company’s development. The team has already made significant strides in researching and developing novel treatments with disease-modifying potential for ALS and other neurodegenerative diseases. I look forward to leveraging my experience and expertise to help drive VectorY's pioneering efforts in this field and be a part of the company’s future growth.”
Pharmafocus
Pharmaceutical Industry news, analysis and insights